We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ultrasensitive Biosensor Detects Cancer

By LabMedica International staff writers
Posted on 04 Jun 2012
An ultrasensitive biosensor has been created that could open up new opportunities for early detection of cancer and personalized medicine tailored to the specific biochemistry of individual patients.

The device, which could be several hundred times more sensitive than other biosensors, combines the attributes of two distinctly different types of sensors, a mechanical sensor, which identifies a biomolecule based on its mass or size, and an electrical sensor that identifies molecules based on their electrical charge.

At Purdue University (West Lafayette, IN, USA) scientists found that the new sensor detects both charged and uncharged biomolecules, allowing a broader range of applications than either type of sensor alone. The sensor's mechanical part is a vibrating cantilever, a sliver of silicon that resembles a tiny diving board. Located under the cantilever is a transistor, which is the sensor's electrical part. The sensor maximizes sensitivity by putting both the cantilever and transistor in a "bias.” The cantilever is biased using an electric field to pull it downward as though with an invisible string.

In other mechanical biosensors, a laser measures the vibrating frequency or deflection of the cantilever, which changes depending on what type of biomolecule lands on the cantilever. Instead of using a laser, the new sensor uses the transistor to measure the vibration or deflection. In early cancer diagnostics, the sensor makes possible the detection of small quantities of DNA fragments and proteins deformed by cancer long before the disease is visible through imaging or other methods. The device is called a Flexure-field effect transistor (FET) biosensor. A key innovation is the elimination of a component called a reference electrode, which is required for conventional electrical biosensors, but cannot be miniaturized, limiting practical applications.

The authors concluded that there are broad ranges of applications that can benefit from the sensitivity gain of the biosensor. For example, the current genome sequencing schemes require polymerase chain reaction (PCR) amplification of DNA strands because of the lower sensitivity of existing biosensors. The high sensitivity of Flexure-FET can eliminate the requirement of multiplication step and hence reduce the cost of sequencing. The study was published on May 23 2012, in the Proceedings of the National Academy of Sciences of the United States of America.

Related Links:

Purdue University


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
New
Automated Coagulation Analyzer
Hemolumi H6

Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
ADLM